<DOC>
	<DOCNO>NCT01353703</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety Infanrix hexa™ ( DTPa-HBV-IPV/Hib ) administer primary vaccination course Indian infant accord 6-10-14 week 2-4-6 month schedule .</brief_summary>
	<brief_title>Immunogenicity Safety Study Infants GlaxoSmithKline Biologicals ' Infanrix Hexa™ ( DTPa-HBV-IPV/Hib ) Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : A male female , include , 6 10 week age time first vaccination Documented administration hepatitis B vaccine dose birth Subjects investigator believe parent ( ) /legally acceptable representative ( ) [ LAR ( ) ] comply requirement protocol Written inform consent obtain parent ( ) /LAR ( ) subject Healthy subject establish medical history clinical examination enter study Born gestation period least 36 week The following criterion check time study entry . If ANYexclusion criterion applies , subject must include study : Child care Use investigational nonregistered product study vaccine within 30 day precede first dose , plan use study period Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose Administration vaccine foreseen study protocol , within 30 day prior first study visit , plan administration study period , exception oral human rotavirus ( HRV ) vaccination allow time study Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Evidence previous diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis Haemophilus influenzae type b ( Hib ) vaccination disease , exception birth dose hepatitis B vaccine oral poliovirus vaccine ( OPV ) per local standard care Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Family history congenital hereditary immunodeficiency History reaction hypersensitivity likely exacerbate component vaccine Major congenital defect serious chronic illness Administration immunoglobulins and/or blood product since birth plan administration study period Acute disease and/or fever time enrolment</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Infanrix hexa™</keyword>
	<keyword>Primary vaccination</keyword>
	<keyword>India</keyword>
	<keyword>combination vaccine</keyword>
	<keyword>infant</keyword>
</DOC>